Hematologic Malignancy
Primary Amyloidosis
CI-CAN-00008290Explore in graph →
HematologicNon-malignant32 active trials
- NCIt
- C3819
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008290Explore in graph →
Clinical trials
106 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07615270 | A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | not yet recruiting | Early Phase 1 | 5 | Stanford UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07626476 | Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis | recruiting | Early Phase 1 | 30 | Beijing Boren HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07085559 |
| Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research |
| recruiting |
| Early Phase 1 |
| 36 |
| Anhui Provincial HospitalOTHER_GOV |
| 1 |
| Jul 25, 2025 |
| clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2026source: clinicaltrials